Wegovy (semaglutide) is an FDA-approved prescription medication for chronic weight management in adults with obesity, or adults with overweight who also have weight-related medical conditions. It is taken along with a reduced calorie diet and increased physical activity.

Wegovy is also approved to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with obesity or overweight and established heart disease.

Wegovy is a GLP-1 receptor agonist that mimics a naturally occurring hormone involved in appetite regulation and blood sugar control.

By acting on appetite centers in the brain, Wegovy can help reduce hunger, increase feelings of fullness, and support more consistent eating patterns when paired with lifestyle changes.

In clinical trials, adults taking Wegovy in combination with lifestyle changes lost an average of 15% of their body weight over 68 weeks. Individual results vary based on dose, metabolic factors, and adherence to recommended dietary changes.

Many individuals notice a reduction in appetite within the first month. As the dose increases over time, weight-related improvements become more noticeable. Most people see meaningful progress between weeks 8–12, with continued results over the full treatment period.

Wegovy may be appropriate for adults with a BMI of 30 or higher, or adults with a BMI of 27 or higher who have weight-related medical concerns such as high blood pressure, high cholesterol, or prediabetes. Eligibility is determined through a provider review.

Common side effects may include nausea, diarrhea, vomiting, constipation, abdominal discomfort, and decreased appetite. These effects are often mild to moderate and typically decrease as the body adjusts to the medication.

A licensed healthcare provider will review safety considerations before prescribing.

No. Both medications contain semaglutide but have different FDA approvals, dosing schedules, and intended uses. Wegovy is approved specifically for chronic weight management at higher doses, while Ozempic is approved for type 2 diabetes.

No. Because Wegovy contains semaglutide, it should not be combined with other semaglutide-containing medications or GLP-1 receptor agonists. A provider will evaluate your medication list before treatment begins.

Coverage varies by plan. Some commercial insurance providers offer partial or full coverage for GLP-1 medications. Many government plans such as Medicare, Medicaid, TRICARE, and VA do not currently cover GLP-1s for weight management.

Good Girl Rx can verify your benefits and present available coverage or cash-pay options.

Begin with a brief online consultation. If medically appropriate, a licensed provider will prescribe Wegovy and coordinate delivery through our partner pharmacy network. Fast, discreet shipping and ongoing clinical support are included with every plan.